{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-024937","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.335178+00:00","generated_at":"2026-06-17T07:49:45.570823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Pharma reports FY2022 net loss $12.7M, cash $4.0M; advances AD04 regulatory meetings","bullets":["Net loss $12.7M for FY2022 vs $19.4M in FY2021; cash and equivalents $4.0M.","R&D expenses down 50% to $4.2M; G&A down 2% to $9.3M.","ONWARD Phase 3: AD04 significantly reduced heavy drinking days in heavy drinkers; identified two target genotypes.","Secured meetings with FDA, Swedish MPA, German BfArM in Q2 2023 for AD04 approval path.","Option to sell Purnovate to Adovate; potential milestones up to $83M plus 19.9% equity stake."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-024937","json":"https://secwatch.observer/filing/0001213900-23-024937.json","markdown":"https://secwatch.observer/filing/0001213900-23-024937.md","text":"https://secwatch.observer/filing/0001213900-23-024937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/0001213900-23-024937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/ea176126-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:49:45.570823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"107d890846a9af09854c4876ccefdf4bbfcde445","claim":"ADIAL PHARMACEUTICALS, INC. reported the 2022 fiscal year ended December 31, 2022 results: net income $12.7 million.","evidence_excerpt":"Net Loss was $12.7 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/0001213900-23-024937-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 2022 fiscal year ended December 31, 2022"},{"label":"Net income","value":"$12.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}